Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard-of-care therapy in relapsed/refractory large B-cell lymphoma Meeting Abstract
| Authors: | Westin, J.; Oluwole, O. O.; Kersten, M. J.; Miklos, D. B.; Perales, M. A.; Ghobadi, A.; Rapoport, A.; Sureda, A.; Jacobson, C. A.; Farooq, U.; van Meerten, T.; Ulrickson, M. L.; Elsawy, M.; Leslie, L. A.; Chaganti, S.; Dickinson, M.; Yang, Y.; Schupp, M. A.; To, C. A.; Locke, F. L. |
| Abstract Title: | Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard-of-care therapy in relapsed/refractory large B-cell lymphoma |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 17 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-10 |
| Language: | English |
| ACCESSION: | WOS:001043181100009 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2023.41.17_suppl.LBA107 |
| Notes: | Meeting Abstract: LBA107 -- Meeting was also available virtually -- Source: Wos |
